VALEANT LUXEMBOURG
GenericsVALEANT LUXEMBOURG is a generic drug manufacturer focused on Immunology. Key products include SILIQ.
VALEANT LUXEMBOURG's Key Drugs
VALEANT LUXEMBOURG's core commercial portfolio centers on SILIQ, spanning Immunology — its most strategically important drugs approved in the last 15 years.
VALEANT LUXEMBOURG's Recent FDA Approvals
New NDA/BLA approvals for VALEANT LUXEMBOURG over the last two years — novel drugs only, excluding generics and label supplements.
VALEANT LUXEMBOURG's Therapeutic Areas
VALEANT LUXEMBOURG's approved drugs and pipeline span 1 therapeutic area, led by Immunology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VALEANT LUXEMBOURG's Top Competitors
VALEANT LUXEMBOURG's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VALEANT LUXEMBOURG Pipeline Snapshot
Active clinical trials for VALEANT LUXEMBOURG across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • SILIQ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1980-06-02
- Latest
- 2026-05-07
- Applications
- 3